<DOC>
	<DOCNO>NCT01415297</DOCNO>
	<brief_summary>The purpose study determine safety maximal tolerate dose NKP-1339 , ruthenium contain compound administer intravenously weekly schedule , patient advance solid tumor . The response treatment population evaluate . In addition , PD PK property compound explore .</brief_summary>
	<brief_title>Dose Escalation Study NKP-1339 Treat Advanced Solid Tumors</brief_title>
	<detailed_description>NKP-1339 novel GRP78 target ruthenium base anti-cancer compound intravenously administer . GRP78 key regulator misfolded protein processing , unregulated cancer cell . In nonclinical anti-tumor study , NKP-1339 show activity many tumor type , include resistant platinum standard anti-cancer agent . This Phase I trial evaluate safety , tolerability , maximum tolerate dose , pharmacokinetics , pharmacodynamics NKP-1339 .</detailed_description>
	<criteria>Patients ≥ 18 year histologically cytologically confirm advanced solid tumor refractory standard therapy sign IRB approve Informed Consent Form ( ICF ) . ECOG PS 0 1 . Adequate hematologic , hepatic renal function Minimum life expectancy ≥ 12 week No supplemental Iron , i.e. , therapeutic part multivitamin regimen . No chemotherapy , immunotherapy , radiotherapy &lt; 4 week , BMTs &lt; 9 month major surgery &lt; 3 week . No symptomatic central nervous system metastasis . No primary brain tumor know brain metastasis unless clinically stable stable reduce dose steroid . No evidence ischemia , MI within past 6 month , significant abnormality ECG . No clinically significant active infection include HIV , hepatitis B , hepatitis C. No Peripheral neuropathy ≥ Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>